PE20230181A1 - Uso de reboxetina para tratar los trastornos del sistema nervioso - Google Patents

Uso de reboxetina para tratar los trastornos del sistema nervioso

Info

Publication number
PE20230181A1
PE20230181A1 PE2022000980A PE2022000980A PE20230181A1 PE 20230181 A1 PE20230181 A1 PE 20230181A1 PE 2022000980 A PE2022000980 A PE 2022000980A PE 2022000980 A PE2022000980 A PE 2022000980A PE 20230181 A1 PE20230181 A1 PE 20230181A1
Authority
PE
Peru
Prior art keywords
reboxetine
nervous system
system disorders
treat nervous
esreboxetine
Prior art date
Application number
PE2022000980A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/740,329 external-priority patent/US20200147093A1/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Priority claimed from PCT/US2020/062560 external-priority patent/WO2021113163A1/en
Publication of PE20230181A1 publication Critical patent/PE20230181A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se describen los metodos para el tratamiento de la narcolepsia con cataplexia, los cuales comprenden la administracion de la reboxetina (la que incluye la esreboxetina) a un ser humano que lo necesite. La reboxetina (la que incluye la esreboxetina) tambien se puede utilizar en la elaboracion de un medicamento para el tratamiento de la narcolepsia con cataplexia. Tambien se dan a conocer en este documento los kits que comprenden una composicion farmaceutica que comprende la reboxetina (la que incluye la esreboxetina) y las instrucciones para usar la composicion farmaceutica para el tratamiento de la narcolepsia con cataplexia en un ser humano.
PE2022000980A 2019-12-03 2020-11-30 Uso de reboxetina para tratar los trastornos del sistema nervioso PE20230181A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962943077P 2019-12-03 2019-12-03
US201962946295P 2019-12-10 2019-12-10
US16/740,329 US20200147093A1 (en) 2018-10-15 2020-01-10 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,409 US11351175B2 (en) 2018-10-15 2020-01-11 Use of reboxetine to treat narcolepsy
US16/740,411 US20200147096A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,410 US20200147095A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
PCT/US2020/062560 WO2021113163A1 (en) 2019-12-03 2020-11-30 Use of reboxetine to treat nervous system disorders

Publications (1)

Publication Number Publication Date
PE20230181A1 true PE20230181A1 (es) 2023-02-01

Family

ID=81851750

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000980A PE20230181A1 (es) 2019-12-03 2020-11-30 Uso de reboxetina para tratar los trastornos del sistema nervioso

Country Status (12)

Country Link
EP (1) EP4069244A4 (es)
JP (1) JP2023504685A (es)
KR (1) KR20220108122A (es)
CN (1) CN114746097A (es)
AU (2) AU2020395082A1 (es)
BR (1) BR112022010677A2 (es)
CA (1) CA3163505A1 (es)
CO (1) CO2022007507A2 (es)
CR (1) CR20220247A (es)
IL (1) IL293536A (es)
MX (1) MX2022006630A (es)
PE (1) PE20230181A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1459751E (pt) * 1999-07-01 2005-11-30 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para tratar as enxaquecas
PL197985B1 (pl) * 1999-07-01 2008-05-30 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
WO2008137923A2 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
DK2968208T3 (da) * 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd Behandling af kataplexi

Also Published As

Publication number Publication date
CA3163505A1 (en) 2021-06-10
MX2022006630A (es) 2022-06-24
EP4069244A1 (en) 2022-10-12
KR20220108122A (ko) 2022-08-02
BR112022010677A2 (pt) 2022-08-16
CO2022007507A2 (es) 2022-06-21
EP4069244A4 (en) 2023-12-20
CN114746097A (zh) 2022-07-12
JP2023504685A (ja) 2023-02-06
AU2020395082A1 (en) 2022-06-09
CR20220247A (es) 2022-08-18
AU2024203676A1 (en) 2024-06-20
IL293536A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
CL2019000510A1 (es) Adenovirus armado con un activador de células t biespecífico (bite).
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
GT201700246A (es) Métodos y kits para tratar la depresión
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000945A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
BR112022007721A2 (pt) Método para o tratamento da demência
CO2022014499A2 (es) Moduladores de nlrp3
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
CL2020000508A1 (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
BR112019004540A2 (pt) método para tratar demência em um paciente, composição farmacêutica, método para tratar demência em um paciente, método para reduzir a probabilidade de desenvolver demência em um paciente, composição para uso no tratamento de demência em um paciente, composição e composição para uso na redução da probabilidade de desenvolver demência em um paciente submetido a uma terapia longa de um fármaco não-esteroide anti-inflamatório ou aspirina
PE20230181A1 (es) Uso de reboxetina para tratar los trastornos del sistema nervioso
CL2022001476A1 (es) Uso de reboxetina para tratar los trastornos del sistema nervioso